Pharmacy Drugs
Recent Posts
- Democrats Push Medical Device Liability Bill
- FDA Investigates Heparin Link in Two Delaware Deaths
- Conflict Of Interest Reported In 29 Percent Of Cancer Studies
- Interim Results Of Abbott’s PROGRESS Study Show Rapid Viral Decline In Dual-Therapy Regimen Of Kaletra(R) (lopinavir/ritonavir) And Raltegravir
- Survival For Prostate Cancer Patients Younger Than 50 Improved By Surgery
Random Posts
- Shire Reports Tolerability And Clinical Effects Results Of Daytrana(R) (methylphenidate Transdermal System) From Study In Adolescents With ADHD
- Spain's Regional Extremadura Government Launches Electronic Prescription System With IBM
- Injured Human Donor Lungs Repaired By Gene Therapy
- Cardica Announces Publication Of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
- Eye Drug Trial Marks Milestone For Southampton's Groundbreaking Research Centre, UK
- Results From 8 Late-Breaking Clinical Trials Presented At Heart Failure 2009
- Study Demonstrated Once-Daily Vyvanse® CII Provided Significant Improvement Of ADHD Symptoms For Children At 13 Hours After Administration
- Pluristem Therapeutics Receives European Regulatory Approval For Placental-Derived Stem Cell Clinical Trial
- Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial
- Mo. House Approves Amendment Allowing Pharmacies To Refuse To Stock EC, Medication Abortion Drugs
Pharmacists’ Association Executive To Receive The Food And Drug Administration’s Commissioner’s Special Citation Award
Posted by: admin in Pharmacy Drugs on October 07th, 2009
John A. Gans, PharmD, Executive Vice President and Chief Executive Officer for the American Pharmacists Association (APhA) has been selected as a recipient of the gov/” rel=”nofollow”>Food and Drug Administration ’s (FDA) Commissioner’s Special Citation Award. The award will be bestowed upon Dr. Gans today during a ceremony at Martin’s Crosswinds, Greenbelt, Maryland.
The award is being presented to Dr. Gans in recognition of 20 years of outstanding leadership in ensuring issues of importance to pharmacists and the APhA are considered in FDA regulatory decision-making.
In congratulating Gans, Dr. Joshua Sharfstein, Acting Commissioner of Food and Drugs, Principal Deputy Commissioner said, “You have been chosen for this award because you have provided invaluable assistance to the FDA. To be selected for special recognition should be most satisfying since accomplishments such as yours impact the well being of the public.”
Dr. Gans has been APhA’s Executive Vice President and Chief Executive Officer since 1989, focusing on positioning pharmacists as valued members of the healthcare team who can improve medication use and advance patient care. Prior to joining APhA Gans served on the faculty and was Dean of the School of Pharmacy at the Philadelphia College of Pharmacy and Science (now known as the University of the Sciences in Philadelphia), where he earned his pharmacy degree in l966 and his doctorate in pharmacy in 1969.
Dr. Gans began his career in 1966 as a community pharmacist in Broomall, Pennsylvania. During 1967-68, Dr. Gans held a residency at the Hospital of the University of Pennsylvania. Following his residency, he became Assistant Director of Pharmacy at the Hospital of the University of Pennsylvania and held that position from 1968-70. He was a pioneer in the area of parenteral nutrition and clinical pharmacy. From 1974 to 1985, he served as the Managing Director of Pharmaservices, a consultant firm to nursing homes.
Dr. Gans has served as the Founding Chairman of the Delaware Valley Regional Poison Control Program, which established a 24-hour regional poison control center in 1985. In 1980-81, he served as President of the Pennsylvania Society of Hospital Pharmacists and, in 1986-87, as President of the American Society of Hospital Pharmacists.
Dr. Gans will step down in July as EVP and CEO of APhA after nearly 20 years of service to the organization.
Source
American Pharmacists Association (APhA)
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.